首页> 外文期刊>Cholesterol >In VivoInflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL
【24h】

In VivoInflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL

机译:体内炎症不会损害HDL的ABCA1介导的胆固醇外流能力

获取原文
       

摘要

HDL provides atheroprotection by facilitating cholesterol efflex from lipid-laden macrophages in the vessel wall. In vitro studies have suggested impaired efflux capacity of HDL following inflammatory changes. We assessed the impact of acute severe sepsis and mild chronic inflammatory disease on the efflux capacity of HDL. We hypothesize that a more severe inflammatory state leads to stronger impaired cholesterol efflux capacity. Using lipid-laden THP1 cells and fibroblasts we were able to show that efflux capacity of HDL from both patients with severe sepsis or with Crohn's disease (active or in remission), either isolated using density gradient ultracentrifugation or using apoB precipitation, was not impaired. Yet plasma levels of HDL cholesterol and apoA-I were markedly lower in patients with sepsis. Based on the current observations we conclude that inflammatory disease does not interfere with the capacity of HDL to mediate cholesterol efflux. Our findings do not lend support to the biological relevance of HDL function changesin vitro.
机译:HDL通过促进血管壁中载脂类巨噬细胞的胆固醇排出而提供抗动脉粥样硬化作用。体外研究表明,炎症改变后HDL的外排能力受损。我们评估了急性严重脓毒症和轻度慢性炎性疾病对HDL外排能力的影响。我们假设更严重的炎症状态会导致更强的胆固醇外排能力受损。使用脂质负载的THP1细胞和成纤维细胞,我们能够证明使用密度梯度超速离心法或apoB沉淀法分离的患有严重败血症或克罗恩病(活动或缓解)的高密度脂蛋白的外排能力没有受到损害。然而,败血症患者的血浆HDL胆固醇和apoA-I水平明显降低。根据目前的观察,我们得出结论,炎症性疾病不会干扰HDL介导胆固醇外流的能力。我们的发现并不支持体外HDL功能改变的生物学相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号